serious infection Imipenem/Cilastatin Sianem Therapeutic Effectiveness Safety
Conditions
Interventions
Subjects receive generic imipenem/cilastatin (Sianem) for treatment,Subjects receive original Tienam for treatment
Treatment,Treatment
Sianem ,Tienam
Sponsors
Siam Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Patients aged 18 years or above admitted to the hospital (2) Patients received imipenem/cilastatin (Tienam or Sianem)
Exclusion criteria
Exclusion criteria: (1) Patient s medical records were not available. (2) Patients received imipenem/cilastatin less than 48 hours. (3) Patients received both generic and original imipenem/cilastatin continuously within the same admission. (4) Patient received carbapenems 14 days prior to the study. (5) Antimicrobial susceptibility testing demonstrating imipenem/cilastatin or carbapenems resistance among the suspected or definite pathogens. (6) Patient died within 48 hours after treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical efficay and safety 2- 28 days during treatment clinical response and safety | — |
Secondary
| Measure | Time frame |
|---|---|
| bacteriological efficacy 2- 28 days during treatment bacteriological culture | — |
Countries
Thailand
Contacts
Public ContactChusana Suankratay
Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University
Outcome results
None listed